Drug Trial Radar · NCT06812754
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Mar 10, 2025
Primary completion
Feb 11, 2026
Study completion Mar 5, 2026
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Feb 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed. The goal of this study is to confirm if fezolinetant helps reduce hot flashes in Chinese women going through menopause. This study will also confirm the safety of fezolinetant and how well the women cope with (tolerate) the treatment. The women will take 1 tablet of the study medicine either fezolinetant or placebo once a day for up to 12 weeks. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it. Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes and night sweats. The women will record this information before, during and after taking the study treatment. During the study, the women will visit the study clinic several times. At each visit they will be asked if they had any medical problems. The women will have general safety checks. At some visits, a breast ultrasound (mammogram), cervical smear, and ultrasound of the womb (uterus) may be done. The last clinic visit will be 3 weeks after the women take their final tablet of the study medicine (fezolinetant or placebo).
Conditions
- Hot Flashes
Interventions
FezolinetantDrug
oral
PlaceboDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in the frequency of moderate to severe Vasomotor Symptoms (VMS) from baseline to week 12Time frame: Baseline to Week 12
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China
Capital Medical University (CMU) - Beijing Shijitan Hospital
Beijing, Beijing Municipality, China
Capital Medical University - Beijing Obstetrics and Gynecology Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Guangzhou Medical University - The Third Affiliated Hospital
Guangzhou, Guangdong, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Shenzhen Maternal & Child Health Hospital
Shenzhen, Guangdong, China
Guangxi Medical University (GXMU) - Liuzhou Renmin Hospital
Liuzhou, Guangxi, China
Liuzhou Worker's Hospital
Liuzhou, Guangxi, China
Hainan Women and Children's Medical Center
Haikou, Hainan, China
The second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Hunan Provincial Maternal and Child Health Care Hospital
Changsha, Hunan, China
Xiangya Hospital, Central South University
Zhuzhou, Hunan, China
Nanjing First Hospital
Nanjing, Jiangsu, China
Southeast University, ZhongDa Hospital
Nanjing, Jiangsu, China
Jiangxi Maternal and Child Health Hospital
Nanchang, Jiangxi, China
Jilin Province FAW General Hospital
Changchun, Jilin, China
Jinan Central Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
Shandong Provincial Hospital
Jinan, Shandong, China
Shanghai First Maternity and Infant Hospital
Shanghai, Shanghai Municipality, China
Shanxi Woman and Children Hospital
Taiyuan, Shanxi, China
The First hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Chengdu Women's and Children's Central Hospital
Chengdu, Sichuan, China
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.